[
  {
    "ts": null,
    "headline": "A Look at Abbott Laboratories’s Valuation Following Revenue Growth and Maintained Outlook",
    "summary": "Abbott Laboratories (ABT) just released its quarterly results, revealing revenue grew nearly 7% over last year, though it missed Wall Street estimates. The company kept its full-year outlook intact and narrowed adjusted EPS guidance. See our latest analysis for Abbott Laboratories. Abbott Laboratories’ 1-day share price return of 1.13% suggests investors remain upbeat after its latest report, even with revenue coming in below expectations. While momentum has softened recently, with a 30-day...",
    "url": "https://finnhub.io/api/news?id=b9d939cfb73f28b8a1bc6de64989486a6562c1fd26bc60aac489fd52309e1104",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762794989,
      "headline": "A Look at Abbott Laboratories’s Valuation Following Revenue Growth and Maintained Outlook",
      "id": 137396619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) just released its quarterly results, revealing revenue grew nearly 7% over last year, though it missed Wall Street estimates. The company kept its full-year outlook intact and narrowed adjusted EPS guidance. See our latest analysis for Abbott Laboratories. Abbott Laboratories’ 1-day share price return of 1.13% suggests investors remain upbeat after its latest report, even with revenue coming in below expectations. While momentum has softened recently, with a 30-day...",
      "url": "https://finnhub.io/api/news?id=b9d939cfb73f28b8a1bc6de64989486a6562c1fd26bc60aac489fd52309e1104"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares",
    "summary": "In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...",
    "url": "https://finnhub.io/api/news?id=1cefe41da28597d92f80f95c4485cd6289f4db7b1cf485d6083ecd5a254d25a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762787433,
      "headline": "How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares",
      "id": 137396620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...",
      "url": "https://finnhub.io/api/news?id=1cefe41da28597d92f80f95c4485cd6289f4db7b1cf485d6083ecd5a254d25a9"
    }
  },
  {
    "ts": null,
    "headline": "Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
    "summary": "PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi",
    "url": "https://finnhub.io/api/news?id=95f63d80a95993ed2144eeac335086e295baad34c0c7439b73fe717dcaac37b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762783200,
      "headline": "Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
      "id": 137394956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi",
      "url": "https://finnhub.io/api/news?id=95f63d80a95993ed2144eeac335086e295baad34c0c7439b73fe717dcaac37b5"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy and Hold Forever",
    "summary": "These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.",
    "url": "https://finnhub.io/api/news?id=473af3b786f5b5a8d00fa40490ccfb01474ab522763fc7287d11d5fd94d77de9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762777800,
      "headline": "2 Top Dividend Stocks to Buy and Hold Forever",
      "id": 137394732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.",
      "url": "https://finnhub.io/api/news?id=473af3b786f5b5a8d00fa40490ccfb01474ab522763fc7287d11d5fd94d77de9"
    }
  }
]